Hudson Therapeutics, Inc.
Clinical-stage biopharmaceutical company founded in 2023 that in-licenses therapeutic assets, advances them through global clinical development, and pursues out-licensing and strategic partnerships. Operates in the U.S. with headquarters in Research Triangle Park, NC, and additional offices in Massachusetts. Leverages nanobody discovery and inflammasome-targeting research originating from its parent company to develop immunomodulatory and biologic candidates.
Industries
N/A
Nr. of Employees
small (1-50)
Hudson Therapeutics, Inc.
Headquarter: 600 Park Office Drive, Durham, NC 27709, USA; Massachusetts Office: 3 Allied Drive, Suite 303, Dedham, MA 02026; Cambridge Office: 245 First Street, Riverview II, 18th Fl, Cambridge, MA 02142
Products
Atopic dermatitis therapeutic candidate (Nugel)
Clinical-stage therapeutic candidate under mid-stage (Phase 2b) evaluation for atopic dermatitis.
CD47/PD-L1 bispecific nanobody candidate
Bispecific single-domain antibody designed to block dual innate and adaptive immune checkpoint pathways for immuno-oncology applications; reported to avoid red blood cell binding due to its structure.
Atopic dermatitis therapeutic candidate (Nugel)
Clinical-stage therapeutic candidate under mid-stage (Phase 2b) evaluation for atopic dermatitis.
CD47/PD-L1 bispecific nanobody candidate
Bispecific single-domain antibody designed to block dual innate and adaptive immune checkpoint pathways for immuno-oncology applications; reported to avoid red blood cell binding due to its structure.
Services
Management of global clinical trials for in-licensed therapeutic candidates following regulatory clearance.
Licensing, partnership development, and out-licensing of therapeutic assets to global pharmaceutical companies.
Rapid selection and generation of nanobody candidates via an in-house screening workflow to accelerate biologic pipeline development.
Management of global clinical trials for in-licensed therapeutic candidates following regulatory clearance.
Licensing, partnership development, and out-licensing of therapeutic assets to global pharmaceutical companies.
Rapid selection and generation of nanobody candidates via an in-house screening workflow to accelerate biologic pipeline development.
Expertise Areas
- Global clinical trial management
- Regulatory interactions for IND-stage programs
- Business development and licensing of therapeutic assets
- Nanobody therapeutics discovery and engineering
Key Technologies
- Nanobody (single-domain antibody) platforms
- High-throughput nanobody screening
- Bispecific antibody/nanobody constructs
- GPCR19–P2X7 inflammasome modulation
News & Updates
Company participation in investor and partnering conferences to engage partners and investors.
Announcements of discussions and engagements with major global pharmaceutical firms for partnerships or licensing.
Announcement of completion of a Phase 2b part 1 clinical trial for an atopic dermatitis therapeutic candidate.
Announcement of initiation of Phase 2b part 2 clinical study for the atopic dermatitis candidate.
Public communication of positive results from a Phase 2b part 1 study for the atopic dermatitis candidate.
Company participation in investor and partnering conferences to engage partners and investors.
Announcements of discussions and engagements with major global pharmaceutical firms for partnerships or licensing.
Announcement of completion of a Phase 2b part 1 clinical trial for an atopic dermatitis therapeutic candidate.
Announcement of initiation of Phase 2b part 2 clinical study for the atopic dermatitis candidate.
Public communication of positive results from a Phase 2b part 1 study for the atopic dermatitis candidate.